A citation-based method for searching scientific literature

Thomas Powles, Kobe C Yuen, Silke Gillessen, Edward E Kadel, Dana Rathkopf, Nobuaki Matsubara, Charles G Drake, Karim Fizazi, Josep M Piulats, Piotr J Wysocki, Gary L Buchschacher, Boris Alekseev, Begoña Mellado, Bogusława Karaszewska, Jennifer F Doss, Grozdana Rasuo, Asim Datye, Sanjeev Mariathasan, Patrick Williams, Christopher J Sweeney. Nat Med 2022
Times Cited: 19







List of co-cited articles
188 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial.
Padmanee Sharma, Russell K Pachynski, Vivek Narayan, Aude Fléchon, Gwenaelle Gravis, Matthew D Galsky, Hakim Mahammedi, Akash Patnaik, Sumit K Subudhi, Marika Ciprotti,[...]. Cancer Cell 2020
111
52

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.
Emmanuel S Antonarakis, Josep M Piulats, Marine Gross-Goupil, Jeffrey Goh, Kristiina Ojamaa, Christopher J Hoimes, Ulka Vaishampayan, Ranaan Berger, Ahmet Sezer, Tuomo Alanko,[...]. J Clin Oncol 2020
275
52

Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.
Tomasz M Beer, Eugene D Kwon, Charles G Drake, Karim Fizazi, Christopher Logothetis, Gwenaelle Gravis, Vinod Ganju, Jonathan Polikoff, Fred Saad, Piotr Humanski,[...]. J Clin Oncol 2017
432
52

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.
Eugene D Kwon, Charles G Drake, Howard I Scher, Karim Fizazi, Alberto Bossi, Alfons J M van den Eertwegh, Michael Krainer, Nadine Houede, Ricardo Santos, Hakim Mahammedi,[...]. Lancet Oncol 2014
974
52

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors.
Karim Fizazi, Charles G Drake, Tomasz M Beer, Eugene D Kwon, Howard I Scher, Winald R Gerritsen, Alberto Bossi, Alfons J M van den Eertwegh, Michael Krainer, Nadine Houede,[...]. Eur Urol 2020
66
47

Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade.
Wassim Abida, Michael L Cheng, Joshua Armenia, Sumit Middha, Karen A Autio, Hebert Alberto Vargas, Dana Rathkopf, Michael J Morris, Daniel C Danila, Susan F Slovin,[...]. JAMA Oncol 2019
290
42

Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study.
A R Hansen, C Massard, P A Ott, N B Haas, J S Lopez, S Ejadi, J M Wallmark, B Keam, J-P Delord, R Aggarwal,[...]. Ann Oncol 2018
193
42

Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Philip W Kantoff, Celestia S Higano, Neal D Shore, E Roy Berger, Eric J Small, David F Penson, Charles H Redfern, Anna C Ferrari, Robert Dreicer, Robert B Sims,[...]. N Engl J Med 2010
42

Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.
Daniel P Petrylak, Yohann Loriot, David R Shaffer, Fadi Braiteh, John Powderly, Lauren C Harshman, Paul Conkling, Jean-Pierre Delord, Michael Gordon, Joseph W Kim,[...]. Clin Cancer Res 2021
30
36

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations.
Fatima Karzai, David VanderWeele, Ravi A Madan, Helen Owens, Lisa M Cordes, Amy Hankin, Anna Couvillon, Erin Nichols, Marijo Bilusic, Michael L Beshiri,[...]. J Immunother Cancer 2018
153
36

Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Oliver Sartor, Johann de Bono, Kim N Chi, Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T Tagawa, Luke T Nordquist, Nitin Vaishampayan, Ghassan El-Haddad,[...]. N Engl J Med 2021
352
36

CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors.
Emmanuel S Antonarakis, Pedro Isaacsson Velho, Wei Fu, Hao Wang, Neeraj Agarwal, Victor Sacristan Santos, Benjamin L Maughan, Roberto Pili, Nabil Adra, Cora N Sternberg,[...]. JCO Precis Oncol 2020
90
31

IL-23 secreted by myeloid cells drives castration-resistant prostate cancer.
Arianna Calcinotto, Clarissa Spataro, Elena Zagato, Diletta Di Mitri, Veronica Gil, Mateus Crespo, Gaston De Bernardis, Marco Losa, Michela Mirenda, Emiliano Pasquini,[...]. Nature 2018
179
31

Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial.
Karim Fizazi, Pablo González Mella, Daniel Castellano, Jose N Minatta, Arash Rezazadeh Kalebasty, David Shaffer, Juan C Vázquez Limón, Héctor M Sánchez López, Andrew J Armstrong, Lisa Horvath,[...]. Eur J Cancer 2022
9
66

Integrative clinical genomics of advanced prostate cancer.
Dan Robinson, Eliezer M Van Allen, Yi-Mi Wu, Nikolaus Schultz, Robert J Lonigro, Juan-Miguel Mosquera, Bruce Montgomery, Mary-Ellen Taplin, Colin C Pritchard, Gerhardt Attard,[...]. Cell 2015
26

Nivolumab plus ipilimumab, with or without enzalutamide, in AR-V7-expressing metastatic castration-resistant prostate cancer: A phase-2 nonrandomized clinical trial.
Eugene Shenderov, Karim Boudadi, Wei Fu, Hao Wang, Rana Sullivan, Alice Jordan, Donna Dowling, Rana Harb, Joseph Schonhoft, Adam Jendrisak,[...]. Prostate 2021
16
31

Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.
James L Gulley, Michael Borre, Nicholas J Vogelzang, Siobhan Ng, Neeraj Agarwal, Chris C Parker, David W Pook, Per Rathenborg, Thomas W Flaig, Joan Carles,[...]. J Clin Oncol 2019
113
26

How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer.
Jacob Stultz, Lawrence Fong. Prostate Cancer Prostatic Dis 2021
31
26

A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone.
Julie N Graff, Tomasz M Beer, Joshi J Alumkal, Rachel E Slottke, William L Redmond, George V Thomas, Reid F Thompson, Mary A Wood, Yoshinobu Koguchi, Yiyi Chen,[...]. J Immunother Cancer 2020
49
26

A Phase Ib Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer.
Lawrence Fong, Michael J Morris, Oliver Sartor, Celestia S Higano, Lance Pagliaro, Ajjai Alva, Leonard J Appleman, Winston Tan, Ulka Vaishampayan, Raphaelle Porcu,[...]. Clin Cancer Res 2021
7
71

Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
725
26

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.
S F Slovin, C S Higano, O Hamid, S Tejwani, A Harzstark, J J Alumkal, H I Scher, K Chin, P Gagnier, M B McHenry,[...]. Ann Oncol 2013
357
26

Expression of PD-L1 in Hormone-naïve and Treated Prostate Cancer Patients Receiving Neoadjuvant Abiraterone Acetate plus Prednisone and Leuprolide.
Carla Calagua, Joshua Russo, Yue Sun, Rachel Schaefer, Rosina Lis, Zhenwei Zhang, Kathleen Mahoney, Glenn J Bubley, Massimo Loda, Mary-Ellen Taplin,[...]. Clin Cancer Res 2017
65
21

Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
Daniel Nava Rodrigues, Pasquale Rescigno, David Liu, Wei Yuan, Suzanne Carreira, Maryou B Lambros, George Seed, Joaquin Mateo, Ruth Riisnaes, Stephanie Mullane,[...]. J Clin Invest 2018
98
21

Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Xin Lu, James W Horner, Erin Paul, Xiaoying Shang, Patricia Troncoso, Pingna Deng, Shan Jiang, Qing Chang, Denise J Spring, Padmanee Sharma,[...]. Nature 2017
296
21

Immunotherapy and Immunotherapy Combinations in Metastatic Castration-Resistant Prostate Cancer.
Dhruv Bansal, Melissa A Reimers, Eric M Knoche, Russell K Pachynski. Cancers (Basel) 2021
20
21

The Tumor Immune Contexture of Prostate Cancer.
Natasha Vitkin, Sarah Nersesian, David Robert Siemens, Madhuri Koti. Front Immunol 2019
91
21

VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.
Jianjun Gao, John F Ward, Curtis A Pettaway, Lewis Z Shi, Sumit K Subudhi, Luis M Vence, Hao Zhao, Jianfeng Chen, Hong Chen, Eleni Efstathiou,[...]. Nat Med 2017
327
21

Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer.
Michael C Haffner, Gunes Guner, Diana Taheri, George J Netto, Doreen N Palsgrove, Qizhi Zheng, Liana Benevides Guedes, Kunhwa Kim, Harrison Tsai, David M Esopi,[...]. Am J Pathol 2018
89
21

Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer.
Sumit K Subudhi, Luis Vence, Hao Zhao, Jorge Blando, Shalini S Yadav, Qing Xiong, Alexandre Reuben, Ana Aparicio, Paul G Corn, Brian F Chapin,[...]. Sci Transl Med 2020
75
21

Randomized Phase II Trial of Sipuleucel-T with or without Radium-223 in Men with Bone-metastatic Castration-resistant Prostate Cancer.
Catherine H Marshall, Wei Fu, Hao Wang, Jong Chul Park, Theodore L DeWeese, Phuoc T Tran, Daniel Y Song, Serina King, Michaella Afful, Julia Hurrelbrink,[...]. Clin Cancer Res 2021
13
30

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.
Robert J Motzer, Nizar M Tannir, David F McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Toni K Choueiri, Elizabeth R Plimack, Philippe Barthélémy, Camillo Porta, Saby George,[...]. N Engl J Med 2018
21

The mutational landscape of lethal castration-resistant prostate cancer.
Catherine S Grasso, Yi-Mi Wu, Dan R Robinson, Xuhong Cao, Saravana M Dhanasekaran, Amjad P Khan, Michael J Quist, Xiaojun Jing, Robert J Lonigro, J Chad Brenner,[...]. Nature 2012
21

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer.
Yi-Mi Wu, Marcin Cieślik, Robert J Lonigro, Pankaj Vats, Melissa A Reimers, Xuhong Cao, Yu Ning, Lisha Wang, Lakshmi P Kunju, Navonil de Sarkar,[...]. Cell 2018
308
21

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
21

Androgen receptor activity in T cells limits checkpoint blockade efficacy.
Xiangnan Guan, Fanny Polesso, Chaojie Wang, Archana Sehrawat, Reed M Hawkins, Susan E Murray, George V Thomas, Breanna Caruso, Reid F Thompson, Mary A Wood,[...]. Nature 2022
28
21

Tumor-infiltrating mesenchymal stem cells: Drivers of the immunosuppressive tumor microenvironment in prostate cancer?
Timothy E Krueger, Daniel L J Thorek, Alan K Meeker, John T Isaacs, W Nathaniel Brennen. Prostate 2019
40
15

Prostate carcinogenesis: inflammatory storms.
Johann S de Bono, Christina Guo, Bora Gurel, Angelo M De Marzo, Karen S Sfanos, Ram S Mani, Jesús Gil, Charles G Drake, Andrea Alimonti. Nat Rev Cancer 2020
55
15

Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer.
Sevda Jafari, Ommoleila Molavi, Houman Kahroba, Mohammad Saied Hejazi, Nasrin Maleki-Dizaji, Siamak Barghi, Seyed Hossein Kiaie, Farhad Jadidi-Niaragh. Cell Mol Life Sci 2020
32
15

Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer.
Colin C Pritchard, Colm Morrissey, Akash Kumar, Xiaotun Zhang, Christina Smith, Ilsa Coleman, Stephen J Salipante, Jennifer Milbank, Ming Yu, William M Grady,[...]. Nat Commun 2014
182
15

The tumor microenvironment and immune responses in prostate cancer patients.
J T W Kwon, R J Bryant, E E Parkes. Endocr Relat Cancer 2021
7
42

A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer.
Ashley E Ross, Paula J Hurley, Phuoc T Tran, Steven P Rowe, Benjamin Benzon, Tanya O' Neal, Carolyn Chapman, Rana Harb, Yelena Milman, Bruce J Trock,[...]. Prostate Cancer Prostatic Dis 2020
21
15

High intratumoral CD8+ T-cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy.
Yuanquan Yang, Kristopher Attwood, Wiam Bshara, James L Mohler, Khurshid Guru, Bo Xu, Pawel Kalinski, Gurkamal Chatta. Prostate 2021
19
15

Association of tumor-infiltrating T-cell density with molecular subtype, racial ancestry and clinical outcomes in prostate cancer.
Harsimar B Kaur, Liana B Guedes, Jiayun Lu, Laneisha Maldonado, Logan Reitz, John R Barber, Angelo M De Marzo, Jeffrey J Tosoian, Scott A Tomlins, Edward M Schaeffer,[...]. Mod Pathol 2018
45
15

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
C Parker, E Castro, K Fizazi, A Heidenreich, P Ost, G Procopio, B Tombal, S Gillessen. Ann Oncol 2020
219
15


Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, Piotr Rutkowski, Jean-Jacques Grob, C Lance Cowey, Christopher D Lao, John Wagstaff, Dirk Schadendorf, Pier F Ferrucci,[...]. N Engl J Med 2017
15

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
15

Comprehensive immunohistochemical analysis of PD-L1 shows scarce expression in castration-resistant prostate cancer.
Christian D Fankhauser, Peter J Schüffler, Silke Gillessen, Aurelius Omlin, Niels J Rupp, Jan H Rueschoff, Thomas Hermanns, Cedric Poyet, Tullio Sulser, Holger Moch,[...]. Oncotarget 2017
35
15

Tumor-Associated Macrophages in Human Breast, Colorectal, Lung, Ovarian and Prostate Cancers.
Irina Larionova, Gulnara Tuguzbaeva, Anastasia Ponomaryova, Marina Stakheyeva, Nadezhda Cherdyntseva, Valentin Pavlov, Evgeniy Choinzonov, Julia Kzhyshkowska. Front Oncol 2020
97
15


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.